BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29915719)

  • 1. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
    Pierpont TM; Limper CB; Richards KL
    Front Oncol; 2018; 8():163. PubMed ID: 29915719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
    Klein C; Jamois C; Nielsen T
    Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 7. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
    Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
    Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
    Chaudhry M; Cheson BD
    Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
    Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
    Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Cheson BD
    J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
    Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
    Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.